- ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
- IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
- ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
- BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
- IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
More ▼
Key statistics
On Tuesday, Immunoprecise Antibodies Ltd (IPA:NMQ) closed at 1.04, 10.64% above the 52 week low of 0.94 set on Dec 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.00 |
---|---|
High | 1.04 |
Low | 0.99 |
Bid | 0.82 |
Offer | 1.08 |
Previous close | 1.04 |
Average volume | 47.98k |
---|---|
Shares outstanding | 26.32m |
Free float | 22.74m |
P/E (TTM) | -- |
Market cap | 27.37m USD |
EPS (TTM) | -0.4139 USD |
Data delayed at least 15 minutes, as of Jul 02 2024 20:59 BST.
More ▼